BIOXYNE LTD Aktie

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, BIOXYNE LTD Aktie had revenue of €17.8m and net profit of €4.17m

(EUR)	December 2025	YoY
Revenue	17.8m	-
Gross profit	6.92m	-
Net profit	4.17m	-
EBITDA	4.67m	-

Fundamentals

Metric	Value
Market capitalization	€131.44m
Number of shares	229.98m
52-week high/low	€0.68 - €0.20
Dividends	No
Beta	0.65
P/E ratio	-
PEG ratio	-
P/B ratio	-
P/S ratio	-

Company profile

Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.